# DLBCL Interim Response Evaluation for Customised Therapy

> **NCT04226937** · — · UNKNOWN · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 150 (estimated)

## Conditions studied

- High-grade B-cell Lymphoma

## Interventions

- **OTHER:** Not Applicable as this is a translational, sample collection study.

## Key facts

- **NCT ID:** NCT04226937
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-17
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-08-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226937, "DLBCL Interim Response Evaluation for Customised Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04226937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*